Navigation Links
12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system)

luding, but not limited to the impact of those on Shire's Attention Deficit and Hyperactivity Disorder ("ADHD") franchise; patents, including but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval, including but not limited to the expected product approval dates of SPD503 (guanfacine extended release) (ADHD) and SPD465 (extended release triple-bead mixed amphetamine salts) (ADHD); Shire's ability to secure new products for commercialization and/or development; Shire's ability to benefit from its acquisition of New River Pharmaceuticals Inc.; and other risks and uncertainties detailed from time to time in Shire plc's filings with the Securities and Exchange Commission, particularly Shire plc's Annual Report on Form 10-K for the year ended December 31, 2006.

Daytrana(TM) is a trademark of Shire Pharmaceuticals Ireland Limited.

CONTACT: Marion E. Glick, +1-212-601-8273, +1-917-301-4206, on site atAPA, , or Jennifer Anello, +1-212-601-8132,+1- 203-470-0836, on site at APA, marion.glick@porternovelli.com jennifer.anello@porternovelli.com

Web site: http://www.shire.com/http://www.DAYTRANA.com/

Ticker Symbol: (NASDAQ-NMS:SHPGY),(Toronto:SHQ.)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
(Date:8/27/2014)... , Aug. 27, 2014 IRIDEX Corporation (NASDAQ: ... James H. Mackaness is scheduled to make an investor ... at 2:55 p.m. Eastern Time on Wednesday, September 3, in ... of the investor presentation will be available in the Investors ... About IRIDEX IRIDEX Corporation was founded ...
(Date:8/27/2014)... Aug. 27, 2014   Auxilium Pharmaceuticals , Inc. (NASDAQ: ... company, today announced that certain members of the executive ... Conference to be held September 8-10, 2014 in ... Chief Executive Officer and President, is scheduled to present ... at 10:55 a.m. ET on Wednesday, September 10, 2014. ...
(Date:8/27/2014)... 27, 2014 Asterias Biotherapeutics Inc. (OTCBB: ASTY) ... Administration (FDA) to initiate a Phase 1/2a clinical trial ... spinal cord injury.  The approved trial follows the successful ... product, and is designed to assess safety and activity ... cervical spinal cord injuries, the first targeted indication for ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 2Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 4Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 5
(Date:8/27/2014)... shapes many aspects of our lives. But in addition ... set during development, but can be altered by our ... our parents and grandparents. , The epigenome consists of ... determine whether genes are expressed or silenced. , This ... but also that it may be possible to diagnose ...
(Date:8/27/2014)... August 27, 2014 Tejal K. Gandhi, MD, ... (NPSF) and the NPSF Lucian Leape Institute, is among ... August 25 issue of Modern Healthcare magazine. Also on the ... Andrew Sussman, MD, MBA; NPSF Lucian Leape Institute members ... who is a member of both the Institute and the ...
(Date:8/27/2014)... August 27, 2014 Scientists at The Scripps Research ... specific signaling pathway can be associated with alcohol dependence. ... gene, called neurofibromatosis type 1 (Nf1), which TSRI scientists ... new research shows Nf1 regulates gamma-aminobutyric acid (GABA), a ... , "This novel and seminal study provides insights ...
(Date:8/27/2014)... Georgia State University’s Center for ... $600,000 grant from the Maternal and Child Health ... to support implementation of the Autism Plan for ... youth with autism spectrum disorder. , In preparing ... Advisory Council composed of key stakeholders from across ...
(Date:8/27/2014)... West Orange, NJ. August 27, 2014. Kessler Foundation ... cultural competence in brain injury research and rehabilitation. ... Krch, PhD: Issues of cultural diversity in acquired ... by Neurorehabilitation . Drs. Lequerica and ... (TBI) Research at Kessler Foundation and co-investigators for ...
Breaking Medicine News(10 mins):Health News:Scientists map the 'editing marks' on fly, worm, human genomes 2Health News:Scientists map the 'editing marks' on fly, worm, human genomes 3Health News:Scientists map the 'editing marks' on fly, worm, human genomes 4Health News:NPSF President Among 100 Most Influential in Health Care 2Health News:NPSF President Among 100 Most Influential in Health Care 3Health News:Scripps Research Institute scientists link alcohol-dependence gene to neurotransmitter 2Health News:Center for Leadership in Disability Awarded $600,000 Grant to Improve Services for Georgia’s Children and Youth with Autism 2
... disease has joined poaching and habitat loss as a ... as they have become restricted to ever-smaller populations. Despite ... closest living relatives from ecological extinction are largely failing, ... threats and find innovative solutions. In response to ...
... CHAPEL HILL, N.C. UNC researchers have discovered how ... heart diseases keeps the critical organ from developing properly. According ... distort the shape of cardiac muscle cells so they are ... study also shows that treatment with a drug that regulates ...
... -- (Feb. 6, 2012) -- Researchers at Rice University and ... into cells that form blood vessels. Their success offers hope ... patches to repair infant hearts. "We want to come ... tissue made from stem cells sloughed off by the infant ...
... A new study analyses the influence that certain birth and ... of breast cancer risk. The results reveal that women born ... taller and thinner than the average girl prior to puberty ... increased risk of developing breast cancer. Although the ...
... , SUNDAY, Feb. 5 (HealthDay News) -- More than 60 ... a social networking site, and many spend more than two ... American Academy of Child and Adolescent Psychiatry. Like many ... teens, and parents need to help their children use these ...
... children in the United States were hospitalized due to child ... School of Medicine researchers report in a new study. ... Pediatrics (published online Feb. 6). Several measures ... abuse, including data from Child Protective Services. But until now ...
Cached Medicine News:Health News:Researchers examine consequences of non-intervention for infectious disease in African great apes 2Health News:Researchers examine consequences of non-intervention for infectious disease in African great apes 3Health News:'ROCK' off: Study establishes molecular link between genetic defect and heart malformation 2Health News:Scientists make strides toward fixing infant hearts 2Health News:Scientists make strides toward fixing infant hearts 3Health News:Women born to older mothers have a higher risk of developing breast cancer 2Health News:Safe Social Networking Tips for Teens 2Health News:Children hospitalized at alarming rate due to abuse 2
... ultra versatile model angulates for vascular ... the height of the support leg, ... post, or double tee foot. Add ... comfort and stability. A convenient bracket ...
... RX600 is a versatile, fully powered orthopaedic ... built-in traction facilities, a powered centre break ... extremely versatile too. ,<br.,In fact the RX600 ... as it is for traction procedures. The ...
... OL1000 Bone Growth Stimulators are portable, battery-powered ... noninvasive treatment of an established nonunion fracture ... and flat bones. , ... of healing of 60.7% in patients with ...
... The EBI OsteoGen surgically implanted bone growth ... of nonunions when surgery is already planned or ... the OsteoGen is totally surgically implanted, patients are ... site 24 hours a day for up to ...
Medicine Products: